Observational studyThe Journal of clinical endocrinology and metabolism2026
Exposure to GLP-1RA and Risk of Structural Progression in Differentiated Thyroid Cancer.
Observational study in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of ambient PM2.5 and its components on the prognosis of colorectal cancer survivors: disease progression and potential mediation pathways.BMC medicine · 2026Article
- Glucagon-like peptide-1 receptor (GLP-1R) overexpression defines a distinct immunogenetic subset in primary and metastatic thyroid cancer: implications for GLP-1R agonist therapy.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
contextGlucagon-like peptide-1 receptor agonists (GLP-1RAs) benefit patients with diabetes mellitus (DM) and obesity. While contraindicated in medullary thyroid cancer, their effect in well-differentiated thyroid cancer (DTC) remains poorly understood.
objectiveTo determine the impact of GLP-1RAs on the risk of DTC recurrence/progression. DESIGN AND
settingRetrospective observational cohort study at a tertiary care center in New York. PARTICIPANTS, INTERVENTION, AND MAIN OUTCOME: Five hundred thirty-six patients with DTC exposed to GLP-1RA were matched 1:1 to 536 patients with DTC never exposed to GLP-1RA by age, date of DTC diagnosis, TNM stage, body mass index (BMI), and DM. A multistate model enabled us to assess the impact of GLP-1RA as a time-dependent variable on the transition of patients with DTC from a "no/stable disease" state to a "recurrence/progression" state.
resultsA total of 1072 patients, median age 49, 71% females, 54% with DM, mean BMI ± SD 35 ± 7 kg/m², 84% with American Joint Committee on Cancer stage I disease, 58% with American Thyroid Association (ATA) intermediate or high risk of recurrence, with median GLP-1RA exposure of 16 months were followed for a median of 69 months. GLP-1RA use was not significantly associated with recurrence or progression of disease in the survival cohort [hazard ratio (HR) = 0.87, 95% confidence interval (CI) 0.62-1.21, P = .39) or the entire cohort (HR = 0.75, 95% CI 0.54-1.03, P = .07) on a multivariable model adjusted for age, ATA risk, radioactive iodine therapy, and DM.
conclusionWe did not find GLP-1RA to be significantly associated with recurrent/progressive DTC. Eligible patients with DTC should not be denied the cardiometabolic benefits of GLP-1RA when clinically indicated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.